SNPX
Price:
$3.45
Market Cap:
$4.53M
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is...[Read more]
Industry
Biotechnology
IPO Date
2020-12-08
Stock Exchange
NASDAQ
Ticker
SNPX
According to Synaptogenix, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 0.34. This represents a change of -95.49% compared to the average of 7.55 of the last 4 quarters.
The mean historical PE Ratio of Synaptogenix, Inc. over the last ten years is -28.68. The current 0.34 PE Ratio has changed -218.56% with respect to the historical average. Over the past ten years (40 quarters), SNPX's PE Ratio was at its highest in in the September 2023 quarter at 38.57. The PE Ratio was at its lowest in in the September 2021 quarter at -131.52.
Average
-28.68
Median
-23.95
Minimum
-84.65
Maximum
-0.52
Discovering the peaks and valleys of Synaptogenix, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.77%
Maximum Annual PE Ratio = -0.52
Minimum Annual Increase = -98.59%
Minimum Annual PE Ratio = -84.65
Year | PE Ratio | Change |
---|---|---|
2023 | -0.52 | -98.59% |
2022 | -37.14 | -56.13% |
2021 | -84.65 | 539.48% |
2020 | -13.24 | -61.81% |
2019 | -34.66 | 1.77% |
The current PE Ratio of Synaptogenix, Inc. (SNPX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-40.77
5-year avg
-34.04
10-year avg
-28.68
Synaptogenix, Inc.’s PE Ratio is greater than Annovis Bio, Inc. (-2.07), greater than Cyclo Therapeutics, Inc. (-0.94), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.10), greater than INmune Bio, Inc. (-3.01), greater than Alzamend Neuro, Inc. (-0.15),
Company | PE Ratio | Market cap |
---|---|---|
-2.07 | $102.73M | |
-0.94 | $19.51M | |
-1.10 | $44.68M | |
-3.01 | $116.32M | |
-0.15 | $1.78M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Synaptogenix, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Synaptogenix, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Synaptogenix, Inc.'s PE Ratio?
How is the PE Ratio calculated for Synaptogenix, Inc. (SNPX)?
What is the highest PE Ratio for Synaptogenix, Inc. (SNPX)?
What is the 3-year average PE Ratio for Synaptogenix, Inc. (SNPX)?
What is the 5-year average PE Ratio for Synaptogenix, Inc. (SNPX)?
How does the current PE Ratio for Synaptogenix, Inc. (SNPX) compare to its historical average?